CUE Cue Biopharma, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1645460 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY401.9%
TTM net income YoY-448.5%
TTM EPS YoY-107.1%
Revenue 3-yr CAGR110.5%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-387.7%
Net margin-579.9%
FCF margin-143.7%
EBITDA margin-384.0%
Returns
ROE-800.4%
ROA-418.0%
ROIC (approx.)—
Asset turnover0.72x
Leverage & solvency
Liabilities / assets42.9%
Debt / equity0.00x
Current ratio3.38x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.25x
Accruals ratio-314.6%
Payout ratio—
Capex / revenue0.3%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $27.47M | $9.29M | $5.49M | $1.25M | $14.94M |
| R&D expense | $37.74M | $36.30M | $40.80M | $38.58M | $41.35M |
| SG&A expense | $16.24M | $14.59M | $16.68M | $16.17M | $17.31M |
| Operating income | -$26.55M | -$41.50M | -$52.15M | -$53.23M | -$43.71M |
| Interest expense | $100,000 | $100,000 | $100,000 | $109,000 | — |
| Pretax income | — | — | — | -$53.01M | -$43.67M |
| Income tax | $500,000 | $0 | — | $0 | $495,000 |
| Net income | -$26.60M | -$40.67M | -$50.73M | -$53.01M | -$44.16M |
| EBITDA | -$25.59M | -$41.10M | -$51.59M | -$52.30M | -$42.45M |
| EPS (basic) | -0.28 | -0.72 | -1.11 | -1.49 | -1.41 |
| EPS (diluted) | -0.28 | -0.72 | -1.11 | -1.49 | -1.41 |
| Weighted avg. shares (diluted) | 94.73M | 56.33M | 45.75M | 35.65M | 31.29M |
| Banking | |||||
| Net interest income | -$357,000 | -$796,000 | -$1.25M | -$713,000 | $0 |
| Balance sheet | |||||
| Cash & equivalents | $27.14M | $22.46M | $48.51M | $51.61M | $64.37M |
| Short-term investments | — | $0 | $0 | $24.68M | $0 |
| Receivables | $5.55M | $945,000 | $1.70M | $57,000 | $3.14M |
| Current assets | $36.98M | $25.14M | $51.45M | $77.19M | $68.47M |
| PP&E, net | $241,000 | $471,000 | $795,000 | $1.50M | $2.11M |
| Total assets | $42.21M | $32.19M | $61.53M | $91.28M | $83.40M |
| Current liabilities | $13.49M | $13.69M | $17.08M | $11.55M | $12.79M |
| Short-term debt | — | $37,000 | $4.00M | $2.00M | — |
| Long-term debt | — | $0 | $4.20M | $8.04M | $0 |
| Total debt | — | $37,000 | $8.20M | $10.04M | $0 |
| Total liabilities | $15.78M | $14.69M | $24.45M | $25.60M | $17.91M |
| Shareholders' equity | $26.43M | $17.50M | $37.09M | $65.68M | $65.49M |
| Net debt | — | -$22.42M | -$40.31M | -$41.58M | -$64.37M |
| Shares outstanding | 3.22M | 61.82M | 47.22M | 47.22M | 32.20M |
| Cash flow statement | |||||
| Operating cash flow | -$21.69M | -$36.33M | -$39.96M | -$41.81M | -$38.84M |
| Capital expenditure | $177,000 | $66,000 | $0 | $171,000 | $913,039 |
| Free cash flow | -$21.86M | -$36.40M | -$39.96M | -$41.98M | -$39.75M |
| Investing cash flow | $75,000 | $32,000 | $25.00M | -$24.61M | $9.11M |
| Financing cash flow | $26.29M | $10.24M | $11.86M | $53.66M | $19.23M |
| Depreciation & amortization | $958,000 | $397,000 | $556,000 | $922,000 | $1.26M |
| Stock-based compensation | $4.74M | $6.85M | $8.18M | $9.50M | $11.52M |
| Share buybacks | — | — | $0 | $200,000 | $750,128 |
Free plan shows the latest 5 periods; Pro shows all 9 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.